By Adam Bonislawski

Vermillion reported this week that it sold an estimated 3,920 OVA1 ovarian cancer tests in the second quarter, a 27 percent spike over the 3,080 tests performed in the first quarter of this year and a 214 percent improvement over the 1,247 tests performed in Q2 2010, the first quarter the company recorded revenues from the diagnostic.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.